What is it about?
CgA has been used as a biomarker in NET patients and retrospective studies are conflicting but most of them report that an increase in plasma CgA predicts tumor progression in neuroendocrine tumor (NET) patients. Prospectively, we investigated if a change in plasma CgA is associated with tumor burden changes in NET patients with disseminated disease.
Featured Image
Why is it important?
In this prospective study of gastroenteropancreatic NET patients, we observed only a weak association between a change in plasma CgA and changes in tumor burden. CgA as a single biomarker was inadequate to predict tumor progression.
Perspectives
There is an unmet need for new and better biomarkers in NET patients both for prognosis and treatment response.
Clinical Chair Professor Henning Gronbaek
Aarhus Universitet
Read the Original
This page is a summary of: Prospective study of chromogranin A as a predictor of progression in patients with pancreatic, small intestinal and unknown primary neuroendocrine tumors., Neuroendocrinology, October 2019, Karger Publishers,
DOI: 10.1159/000503833.
You can read the full text:
Contributors
The following have contributed to this page
